echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Phase I clinical study shows that the neutralizing antibody "MW33" injection can effectively block the new coronavirus

    Phase I clinical study shows that the neutralizing antibody "MW33" injection can effectively block the new coronavirus

    • Last Update: 2021-08-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Recently, Fudan University professor Lu Hongzhou’s clinical trial of an effective drug neutralizing antibody "MW33 injection" for the prevention and treatment of new coronavirus infections showed that its safety, tolerability, and pharmacokinetic characteristics have a stable antibody structure.


    In addition to vaccines, the new coronavirus neutralizing antibody is one of the generally recognized effective drugs for the prevention and treatment of new coronavirus infections


    In order to further evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of single administration of "MW33 injection" in healthy subjects, and to provide data support for the smooth development of phase II-III clinical trials, After rigorous screening, the study finally enrolled 42 healthy volunteers, who were divided into 5 dose groups for climbing tests, namely, single injections of 4, 10, 20, 40, and 60 mg per kilogram of body weight were given.


    In terms of pharmacokinetics, the half-lives of the 5 dose groups of 4, 10, 20, 40, and 60 mg were 673.


    In terms of immunogenicity results, 6 samples from a total of 3 subjects tested positive for ADA (indicating that a certain biological drug was used in the human body to produce drug-resistant antibodies), of which 2 cases were in the experimental drug group, and none of them were immunized.


    It is reported that the new coronavirus neutralizing antibody is a therapeutic antibody.


    Related paper information: https://doi.


    https://doi.
    org/10.
    1080/22221751.
    2021.
    1960900
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.